

BILL SUMMARY
2nd Session of the 58th Legislature

Bill No.:	SB1467
Version:	ENGR
Request Number:	
Author:	Rep. Caldwell, Chad and Sen. David
Date:	4/6/2022
Impact:	\$200,000 to state, see below

Research Analysis

SB 1467 requires the Oklahoma Health Care Authority to conduct an annual review of all medications and forms of treatment for sickle cell disease and services for enrollees with a diagnosis of sickle cell disease. The measure provides the required criteria for the annual review.

The Authority is directed to solicit and consider input from the general public, with specific emphasis on seeking input from persons or groups with knowledge and experience in the area of sickle cell disease treatment. Additionally, the Authority will utilize the Oklahoma State Health Information Network and Exchange to collect information. The Authority is required to submit a report to the President Pro Tempore of the Senate and the Speaker of the House of Representatives for distribution to the appropriate subject matter committees that details the Authority's findings from the annual review.

Prepared By: Dan Brooks

Fiscal Analysis

From Oklahoma Health Care Authority: From a medications perspective this review already exists. From a treatment perspective, it likely does not. We assume this would require a vendor for the annual review. If we have to have a number for it, let's assume that would be a cost of \$400K, state cost \$200K.

Prepared By: Stacy Johnson

Other Considerations

None.